Cornercap Investment Counsel Inc. Makes New Investment in Black Diamond Therapeutics, Inc. (NASDAQ:BDTX)

Cornercap Investment Counsel Inc. acquired a new stake in shares of Black Diamond Therapeutics, Inc. (NASDAQ:BDTX) during the 4th quarter, according to its most recent 13F filing with the SEC. The firm acquired 82,784 shares of the company’s stock, valued at approximately $233,000.

A number of other institutional investors and hedge funds have also bought and sold shares of the business. Jump Financial LLC purchased a new position in Black Diamond Therapeutics in the 3rd quarter worth approximately $32,000. Cubist Systematic Strategies LLC boosted its position in shares of Black Diamond Therapeutics by 25.8% during the second quarter. Cubist Systematic Strategies LLC now owns 15,804 shares of the company’s stock worth $39,000 after acquiring an additional 3,244 shares during the last quarter. Walleye Capital LLC purchased a new position in Black Diamond Therapeutics during the third quarter valued at $44,000. AQR Capital Management LLC increased its holdings in Black Diamond Therapeutics by 34.4% in the 2nd quarter. AQR Capital Management LLC now owns 18,663 shares of the company’s stock valued at $46,000 after acquiring an additional 4,773 shares during the last quarter. Finally, Algert Global LLC purchased a new stake in Black Diamond Therapeutics in the 3rd quarter worth $57,000. 95.47% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently commented on the company. HC Wainwright reiterated a “buy” rating and issued a $12.00 target price (up from $11.00) on shares of Black Diamond Therapeutics in a research report on Monday, March 18th. Wedbush raised their target price on shares of Black Diamond Therapeutics from $10.00 to $16.00 and gave the company an “outperform” rating in a report on Monday, April 8th.

Black Diamond Therapeutics Price Performance

Shares of NASDAQ BDTX opened at $5.70 on Thursday. Black Diamond Therapeutics, Inc. has a 1-year low of $1.43 and a 1-year high of $6.85. The business’s 50 day moving average is $4.84 and its two-hundred day moving average is $3.38. The stock has a market capitalization of $294.80 million, a P/E ratio of -3.03 and a beta of 2.64.

Black Diamond Therapeutics (NASDAQ:BDTX) last issued its quarterly earnings results on Tuesday, March 12th. The company reported ($0.34) earnings per share for the quarter, topping the consensus estimate of ($0.47) by $0.13. As a group, equities research analysts anticipate that Black Diamond Therapeutics, Inc. will post -1.71 earnings per share for the current fiscal year.

Black Diamond Therapeutics Company Profile

Black Diamond Therapeutics, Inc, a clinical-stage oncology medicine company, focuses on the discovery and development of MasterKey therapies for patients with genetically defined tumors. The company's lead product candidate is BDTX-1535, a brain-penetrant epidermal growth factor receptor MasterKey inhibitor, which is in phase 2 clinical trial for the treatment of epidermal growth factor receptor mutant non-small cell lung cancer, as well as phase 1 clinical trial to treat glioblastoma.